Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Allison A. Muller
Venetoclax: Another Oral Therapy Option for Patients With CLL
Pharmacy Today
Related publications
Pcn84 - Total Cost of Care and Budget Impact for Patients With CLL Treated With Venetoclax
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
An Undetectable Pb MRD Status Should Be the Therapeutic Goal With Venetoclax Therapy in Relapsed/ Refractory CLL
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Venetoclax–Obinutuzumab Elicits High Response Rates in CLL
Cancer Discovery
Oncology
Bendamustine (B), Followed by Obinutuzumab (G) and Venetoclax (A) in Patients With Chronic Lymphocytic Leukemia (Cll): Cll2-Bag Trial of the German CLL Study Group (Gcllsg)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Fixed-Duration Venetoclax Plus Obinutuzumab Improves PFS and Minimal Residual Disease Negativity in Patients With Previously Untreated CLL and Comorbidities
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Clinical Outcomes From Venetoclax Based Therapy in Patients With Relapsed/Refractory B-Cell Lymphomas
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Biclonal IGHV -4-34 Variant Hairy Cell Leukemia and CLL - Successful Treatment With Ibrutinib and Venetoclax
American Journal of Hematology
Hematology
Clinical Benefit of Antisense Therapy in a Phase III Trial in Patients With CLL
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
Combined Aspirin–Oral Anticoagulant Therapy Compared With Oral Anticoagulant Therapy Alone Among Patients at Risk for Cardiovascular Disease
Archives of Internal Medicine
